Epidemiologic Evaluation of Cardiovascular Risk in Patients Receiving Milnacipran, Venlafaxine, or Amitriptyline: Evidence from French Health Data.

Abstract

BACKGROUND:

Milnacipran, a selective serotonin and norepinephrine reuptake inhibitor, is approved by the Food and Drug Administration for the management of fibromyalgia. It has been available for many years in several countries outside the US for the treatment of depression.

OBJECTIVE:

To conduct population-based analyses comparing the risk of serious cardiovascular (CV) events (eg, acute myocardial infarction, stroke, congestive heart failure) associated with treatment with milnacipran compared with venlafaxine and amitriptyline, 2 other commonly prescribed drugs that also inhibit reuptake of norepinephrine and serotonin.

METHODS:

Information from the French Thales electronic health record database from 2001 to 2007 was used. Patients with 1 or more prescriptions for milnacipran, venlafaxine, or amitriptyline; 180 or more days of continuous eligibility prior to the first prescription; and no prior CV event diagnoses during the 180-day baseline period were included. A retrospective, matched-cohort design was employed. The incidence rates of CV events between cohorts receiving milnacipran, venlafaxine, and amitriptyline were compared using unadjusted incidence rate ratio (IRR) and adjusted conditional IRR based on Poisson regression.

RESULTS:

We identified 4452 milnacipran-venlafaxine and 3761 milnacipran-amitriptyline matched pairs. The matched cohorts had similar baseline characteristics. The unadjusted IRRs of any CV events, comparing milnacipran with venlafaxine or amitriptyline, were 1.02 (95% CI 0.73 to 1.44) and 1.30 (95% CI 0.90 to 1.89), respectively. Adjusted IRRs confirmed the statistical similarity in the CV event risk between milnacipran and venlafaxine (adjusted IRR = 1.29, 95% CI 0.76 to 2.17) or amitriptyline (adjusted IRR = 1.06, 95% CI 0.59 to 1.89).

CONCLUSIONS:

This French population-based study found that the risk of CV events was not significantly different for patients receiving milnacipran versus those receiving venlafaxine or amitriptyline.

• Authors: Philip J Mease, Peter J Zimetbaum, Mei Sheng Duh, Francis Vekeman, Annie Guérin, Mariette Boerstoel-Streefland, Wenjun Jiang, Patrick Lefebvre
• Journal: The Annals of pharmacotherapy (Ann Pharmacother) Vol. 45 Issue 2 Pg. 179-88 (Feb 2011) ISSN: 1542-6270 [Electronic] United States
• PMID: 21304035 (Publication Type: Journal Article)
• Copyright: © 2011 SAGE Publications.

Chemical References

• Adrenergic Uptake Inhibitors
• Antidepressive Agents
• Cyclopropanes
• Serotonin Uptake Inhibitors
• Amitriptyline
• Venlafaxine Hydrochloride
• Milnacipran

Topics

• Adrenergic Uptake Inhibitors (adverse effects)
• Adult
• Amitriptyline (adverse effects)
• Antidepressive Agents (adverse effects)
• Cardiovascular Diseases (chemically induced, epidemiology)
• Cyclopropanes (adverse effects)
• Female
• Heart Failure (chemically induced, epidemiology)
• Humans
• Male
• Middle Aged
• Milnacipran
• Myocardial Infarction (chemically induced, epidemiology)
• Retrospective Studies
• Risk
• Selective Serotonin Reuptake Inhibitors (adverse effects)
• Stroke (chemically induced, epidemiology)
• United States
• Venlafaxine Hydrochloride (therapeutic use)